vs
Side-by-side financial comparison of BayCom Corp (BCML) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
BayCom Corp is the larger business by last-quarter revenue ($25.9M vs $18.6M, roughly 1.4× SCYNEXIS INC). SCYNEXIS INC runs the higher net margin — 65.7% vs 26.5%, a 39.3% gap on every dollar of revenue. On growth, SCYNEXIS INC posted the faster year-over-year revenue change (1808.5% vs 9.4%). Over the past eight quarters, SCYNEXIS INC's revenue compounded faster (268.5% CAGR vs 2.9%).
BayCom Corp is a U.S.-headquartered bank holding company operating through its wholly owned subsidiary Bay Commercial Bank. It primarily serves small and medium-sized enterprises and retail customers across Northern California, offering commercial lending, deposit products, personal banking services, and localized wealth management solutions.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
BCML vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $25.9M | $18.6M |
| Net Profit | $6.9M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | 36.6% | 56.3% |
| Net Margin | 26.5% | 65.7% |
| Revenue YoY | 9.4% | 1808.5% |
| Net Profit YoY | 12.1% | 376.5% |
| EPS (diluted) | $0.63 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $25.9M | $18.6M | ||
| Q3 25 | $25.7M | $334.0K | ||
| Q2 25 | $24.7M | $1.4M | ||
| Q1 25 | $24.3M | $257.0K | ||
| Q4 24 | $23.7M | $977.0K | ||
| Q3 24 | $25.6M | $660.0K | ||
| Q2 24 | $23.8M | $736.0K | ||
| Q1 24 | $24.5M | $1.4M |
| Q4 25 | $6.9M | $12.3M | ||
| Q3 25 | $5.0M | $-8.6M | ||
| Q2 25 | $6.4M | $-6.9M | ||
| Q1 25 | $5.7M | $-5.4M | ||
| Q4 24 | $6.1M | — | ||
| Q3 24 | $6.0M | $-2.8M | ||
| Q2 24 | $5.6M | $-14.5M | ||
| Q1 24 | $5.9M | $411.0K |
| Q4 25 | 36.6% | 56.3% | ||
| Q3 25 | 26.3% | -2516.5% | ||
| Q2 25 | 35.3% | -701.0% | ||
| Q1 25 | 31.6% | -3350.2% | ||
| Q4 24 | 34.2% | — | ||
| Q3 24 | 32.4% | -1563.6% | ||
| Q2 24 | 31.9% | -1255.0% | ||
| Q1 24 | 33.3% | -692.5% |
| Q4 25 | 26.5% | 65.7% | ||
| Q3 25 | 19.5% | -2572.2% | ||
| Q2 25 | 25.8% | -504.8% | ||
| Q1 25 | 23.4% | -2097.7% | ||
| Q4 24 | 25.9% | — | ||
| Q3 24 | 23.5% | -425.5% | ||
| Q2 24 | 23.6% | -1964.4% | ||
| Q1 24 | 24.0% | 29.9% |
| Q4 25 | $0.63 | $0.25 | ||
| Q3 25 | $0.46 | $-0.17 | ||
| Q2 25 | $0.58 | $-0.14 | ||
| Q1 25 | $0.51 | $-0.11 | ||
| Q4 24 | $0.55 | — | ||
| Q3 24 | $0.54 | $-0.06 | ||
| Q2 24 | $0.50 | $-0.30 | ||
| Q1 24 | $0.51 | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $40.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $338.6M | $49.4M |
| Total Assets | $2.6B | $59.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $40.0M | ||
| Q3 25 | — | $37.9M | ||
| Q2 25 | — | $44.8M | ||
| Q1 25 | — | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | $338.6M | $49.4M | ||
| Q3 25 | $334.3M | $36.4M | ||
| Q2 25 | $330.6M | $44.5M | ||
| Q1 25 | $329.3M | $50.5M | ||
| Q4 24 | $324.4M | $55.1M | ||
| Q3 24 | $321.7M | $58.5M | ||
| Q2 24 | $315.3M | $60.4M | ||
| Q1 24 | $314.2M | $74.1M |
| Q4 25 | $2.6B | $59.0M | ||
| Q3 25 | $2.6B | $51.1M | ||
| Q2 25 | $2.6B | $60.7M | ||
| Q1 25 | $2.6B | $67.9M | ||
| Q4 24 | $2.7B | $90.6M | ||
| Q3 24 | $2.6B | $99.0M | ||
| Q2 24 | $2.6B | $107.8M | ||
| Q1 24 | $2.6B | $118.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $31.8M | $18.4M |
| Free Cash FlowOCF − Capex | $30.1M | — |
| FCF MarginFCF / Revenue | 116.2% | — |
| Capex IntensityCapex / Revenue | 6.7% | — |
| Cash ConversionOCF / Net Profit | 4.64× | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | $51.1M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $31.8M | $18.4M | ||
| Q3 25 | $7.3M | $-8.7M | ||
| Q2 25 | $6.4M | $-7.5M | ||
| Q1 25 | $9.3M | $-7.5M | ||
| Q4 24 | $30.4M | $-24.0M | ||
| Q3 24 | $9.6M | $765.0K | ||
| Q2 24 | $7.7M | $-10.9M | ||
| Q1 24 | $5.1M | $-4.0M |
| Q4 25 | $30.1M | — | ||
| Q3 25 | $6.2M | — | ||
| Q2 25 | $5.6M | — | ||
| Q1 25 | $9.1M | — | ||
| Q4 24 | $28.7M | — | ||
| Q3 24 | $9.4M | — | ||
| Q2 24 | $7.4M | — | ||
| Q1 24 | $3.9M | — |
| Q4 25 | 116.2% | — | ||
| Q3 25 | 24.3% | — | ||
| Q2 25 | 22.8% | — | ||
| Q1 25 | 37.6% | — | ||
| Q4 24 | 121.1% | — | ||
| Q3 24 | 36.6% | — | ||
| Q2 24 | 31.2% | — | ||
| Q1 24 | 16.1% | — |
| Q4 25 | 6.7% | — | ||
| Q3 25 | 4.3% | — | ||
| Q2 25 | 3.0% | — | ||
| Q1 25 | 0.6% | — | ||
| Q4 24 | 7.2% | — | ||
| Q3 24 | 1.0% | — | ||
| Q2 24 | 1.0% | — | ||
| Q1 24 | 4.7% | — |
| Q4 25 | 4.64× | 1.50× | ||
| Q3 25 | 1.47× | — | ||
| Q2 25 | 1.00× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 4.96× | — | ||
| Q3 24 | 1.60× | — | ||
| Q2 24 | 1.37× | — | ||
| Q1 24 | 0.86× | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BCML
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
